Health Care • Biotechnology: Pharmaceutical Preparations
$4.12 ▼ -0.10
(-2.37%)
MKT CAP: $398.5M • VOL: 756.3K
52W L $1 52W H $11
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
RZLT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$79.9M | -$70.4M | -$56.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$74.4M | -$68.5M | -$51.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$69.1M | -$57.4M | -$44.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$69.1M | -$57.4M | -$44.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.9M | $8.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $128.0M | $99.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RZLT.